Drugs / Brivanib
Brivanib
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT03895788 | Jan → Dec 2019 | ovarian cancer | Hunan Cancer Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT01540461 | Mar 2012 → Nov 2013 | hepatocellular carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01046864 | Feb 2010 → Jun 2014 | digestive system cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00435669 | Sep 2007 → Jun 2008 | neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00437424 | Jul 2007 → Jun 2010 | hepatocellular carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00207051 | Jan 2006 → Dec 2008 | colorectal cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00207103 | Sep 2004 → Oct 2007 | metastatic neoplasm, neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00437437 | May 2000 → May 2008 | neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04212221 | Apr 2020 → Apr 2022 | hepatocellular carcinoma | Zai Lab (Shanghai) Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 28 trials | ||||||
| Phase 2 | NCT04395612 | May 2020 → Apr 2022 | cervical cancer | Chongqing University Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03516071 | May 2017 → Nov 2018 | hepatocellular carcinoma | Zai Lab (Shanghai) Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01253668 | Nov 2011 → Sep 2013 | renal cell carcinoma | Abramson Cancer Center at Penn Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01367275 | Aug 2011 → Nov 2013 | colorectal adenocarcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT01267253 | Apr 2011 → Feb 2014 | cervical adenosquamous carcinoma | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00888173 | Jul 2009 → Jul 2016 | endometrial clear cell adenocarcinoma, endometrial mixed adenocarcinoma, endometrial mucinous adenocarcinoma, endometrial serous adenocarcinoma +3 | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00633789 | Jun 2008 → Feb 2012 | ampulla of vater cancer, gastroesophageal adenocarcinoma, non-small cell lung carcinoma, soft tissue sarcoma +1 | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00355238 | Dec 2006 → Apr 2010 | hepatocellular carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT01108705 | May 2010 → Oct 2013 | hepatocellular carcinoma | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 3 | NCT00825955 | Feb 2009 → Nov 2011 | liver cancer | Bristol-Myers Squibb | Completed | Missed primary |
| Comparator or background therapy5 trials | ||||||
| Phase 1 | NCT00390936 Comparator | Oct 2007 → Mar 2010 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT00594984 Comparator | May 2008 → Dec 2012 | colorectal cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00908752 Comparator | Jul 2009 → Sep 2012 | hepatocellular carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00858871 Comparator | May 2009 → Jun 2012 | hepatocellular carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00640471 Comparator | May 2008 → Sep 2011 | colorectal cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2018-09-26 | Zai Lab (Shanghai) Co., Ltd. | Results Zai Lab Presents Interim Results of its ongoing Phase 2 study of ZL-2301 (brivanib) in Chinese Patients with Advanced Hepatocellular Carcinoma (HCC) at the 21st Annual Meeting of the Chinese Society of Clinical Oncology zailaboratory.com ↗
Results from the study show ZL-2301 continues to demonstrate evidence of anti-tumor activity with a manageable safety profile in Chinese patients. |
| 2012-07-19 | Bristol-Myers Squibb | Results BRISK-FL Study with Investigational Compound Brivanib in Hepatocellular Carcinoma Does Not Meet Overall Survival Primary Endpoint bms.com ↗
The study did not meet its primary overall survival objective based upon a non-inferiority statistical design. |
| 2011-12-22 | Bristol-Myers Squibb | Results BRISK-PS Study with Investigational Compound Brivanib in Hepatocellular Carcinoma Completed bms.com ↗
did not meet the primary endpoint of improving overall survival versus placebo. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-09-26 | Zai Lab (Shanghai) Co., Ltd. | Zai Lab Presents Interim Results of its ongoing Phase 2 study of ZL-2301 (brivanib) in Chinese Patients with Advanced Hepatocellular Carcinoma (HCC) at the 21st Annual Meeting of the Chinese Society of Clinical Oncology zailaboratory.com ↗ |
| 2012-07-19 | Bristol-Myers Squibb | BRISK-FL Study with Investigational Compound Brivanib in Hepatocellular Carcinoma Does Not Meet Overall Survival Primary Endpoint bms.com ↗ |
| 2011-12-22 | Bristol-Myers Squibb | BRISK-PS Study with Investigational Compound Brivanib in Hepatocellular Carcinoma Completed bms.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | brivanib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00633789 ↗ |
| Known as | BMS582664 | “A Phase III Randomized Study of Brivanib Alaninate (BMS-582664) in Combination With Cetuximab” NCT00640471 ↗1“Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor” NCT00888173 ↗ |
| Known as | brivanib alaninate | “Patients receive oral brivanib alaninate daily in the absence of disease progression or unacceptable toxicity.” NCT01253668 ↗ |
| Action | Inhibit | “a dual VEGFR and FGFR inhibitor, brivanib” PMID 21131369 ↗ Dec 2010 |
| Modality | Small molecule | “The addition of brivanib, a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor and fibroblast growth factor receptor” PMID 23690424 ↗ May 2013 |
| Route | Oral | “Tablets, Oral” NCT00207103 ↗ |